Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mitchell C Benson

Showing results (121-130 of 136) with videos related to

Pageof 14
Sort By:
Urology|March 27, 2007
Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternativesVinai Gondi, Israel Deutsch, Mahesh Mansukhani, et al.
The Journal of Urology|December 3, 2014
ΔNp63 expression is a protective factor of progression in clinical high grade T1 bladder cancerJosep M Gaya, Juan M López-Martínez, Orit Karni-Schmidt, et al.
The Journal of Urology|July 5, 2014
Phase II trial of intravesical nanoparticle albumin bound paclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after bacillus Calmette-Guérin treatment failureJames M McKiernan, Dara D Holder, Rashed A Ghandour, et al.
Urologic Oncology|July 13, 2015
Validation of a frailty index in patients undergoing curative surgery for urologic malignancy and comparison with other risk stratification toolsDanny Lascano, Jamie S Pak, Max Kates, et al.
Nature Cell Biology|September 22, 2014
Single luminal epithelial progenitors can generate prostate organoids in cultureChee Wai Chua, Maho Shibata, Ming Lei, et al.
Cancer|November 24, 2004
Society of Urologic Oncology position statement: redefining the management of hormone-refractory prostate carcinomaSam S Chang, Mitchell C Benson, Steven C Campbell, et al.
Science Translational Medicine|September 13, 2013
A molecular signature predictive of indolent prostate cancerShazia Irshad, Mukesh Bansal, Mireia Castillo-Martin, et al.
The Prostate|October 21, 2015
Predictors of biochemical recurrence in pT3b prostate cancer after radical prostatectomy without adjuvant radiotherapyMatthew J Pagano, Michael J Whalen, David J Paulucci, et al.
The New England Journal of Medicine|October 8, 2004
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancerDaniel P Petrylak, Catherine M Tangen, Maha H A Hussain, et al.
Journal of the National Cancer Institute|April 20, 2006
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16Daniel P Petrylak, Donna Pauler Ankerst, Caroline S Jiang, et al.
Pageof 14

Showing results (121-130 of 136) with videos related to

Sort By:
Pageof 14
Urology|March 27, 2007
Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternativesVinai Gondi, Israel Deutsch, Mahesh Mansukhani, et al.
The Journal of Urology|December 3, 2014
ΔNp63 expression is a protective factor of progression in clinical high grade T1 bladder cancerJosep M Gaya, Juan M López-Martínez, Orit Karni-Schmidt, et al.
The Journal of Urology|July 5, 2014
Phase II trial of intravesical nanoparticle albumin bound paclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after bacillus Calmette-Guérin treatment failureJames M McKiernan, Dara D Holder, Rashed A Ghandour, et al.
Urologic Oncology|July 13, 2015
Validation of a frailty index in patients undergoing curative surgery for urologic malignancy and comparison with other risk stratification toolsDanny Lascano, Jamie S Pak, Max Kates, et al.
Nature Cell Biology|September 22, 2014
Single luminal epithelial progenitors can generate prostate organoids in cultureChee Wai Chua, Maho Shibata, Ming Lei, et al.
Cancer|November 24, 2004
Society of Urologic Oncology position statement: redefining the management of hormone-refractory prostate carcinomaSam S Chang, Mitchell C Benson, Steven C Campbell, et al.
Science Translational Medicine|September 13, 2013
A molecular signature predictive of indolent prostate cancerShazia Irshad, Mukesh Bansal, Mireia Castillo-Martin, et al.
The Prostate|October 21, 2015
Predictors of biochemical recurrence in pT3b prostate cancer after radical prostatectomy without adjuvant radiotherapyMatthew J Pagano, Michael J Whalen, David J Paulucci, et al.
The New England Journal of Medicine|October 8, 2004
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancerDaniel P Petrylak, Catherine M Tangen, Maha H A Hussain, et al.
Journal of the National Cancer Institute|April 20, 2006
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16Daniel P Petrylak, Donna Pauler Ankerst, Caroline S Jiang, et al.
Pageof 14